\n<\/p>\n
Identified for being one of many happiest nations on this planet, Denmark has now turn into a major hub for\u00a0biotech in Europe. In the previous few years, the nation\u2019s life sciences sector has accelerated its output of high-quality analysis, and the nation\u00a0presently ranks\u00a0sixteenth\u00a0globally\u00a0for organic sciences-related output in 2026.\u00a0\u00a0<\/p>\n
Following the instance of Danish pharma large Novo Nordisk \u2013 which by itself helped to lift Denmark\u2019s gross home product (GDP) after the\u00a0success of its weight reduction drug\u00a0Wegovy \u2013 many biotech firms in Denmark are striving to deliver forth the following large breakthrough within the biopharma trade.\u00a0\u00a0\u00a0<\/p>\n
On this article, we\u00a0look\u00a0at 11 of the very best biotech firms primarily based in Denmark.\u00a0\u00a0<\/p>\n
Know-how: Antibody-drug conjugates\u00a0\u00a0Illness space: Oncology\u00a0\u00a0Latest information: Raised $75 million in collection C funding\u00a0<\/p>\n
Adcendo\u00a0is advancing a pipeline of first- and best-in-class antibody-drug conjugates (ADC) throughout stable epithelial tumors and most cancers with mesenchymal origin, with three packages in scientific improvement and\u00a0extra\u00a0discovery property progressing towards IND research.\u00a0<\/p>\n
The corporate\u2019s three packages are: ADCE-T02, concentrating on tissue issue, which is overexpressed in a broad vary of stable tumors, together with head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal most cancers and non-small cell lung most cancers; ADCE-D01, concentrating on\u00a0uPARAP, which is overexpressed in excessive unmet want cancers, together with tender tissue sarcoma and different cancers of mesenchymal origin; and ADCE-B05, the goal for which is undisclosed, and it’s presently being evaluated preclinically in squamous cell stable tumors.\u00a0<\/p>\n
ADCE-T02 is presently being evaluated as a monotherapy in a section 1 trial in sufferers with superior stable tumors. The primary sufferers have already been enrolled within the cohort growth\u00a0portion\u00a0throughout a number of stable tumor indications. In the meantime, ADCE-D01 is presently being evaluated as a monotherapy in a section 1 examine in sufferers with metastatic and\/or unresectable tender tissue\u00a0sarcoma, and\u00a0was not too long ago granted quick monitor designation and orphan drug designation by the U.S. Meals and Drug Administration (FDA).\u00a0<\/p>\n
In April 2026, the Danish\u00a0ADC firm\u00a0introduced that it had\u00a0raised\u00a0$75 million in collection C funding to assist the development of its packages by upcoming scientific milestones.\u00a0\u00a0<\/p>\n
Know-how: Peptide therapies\u00a0\u00a0Illness space: Weight problems\u00a0\u00a0Latest information: Efficiently accomplished section 1 trial of lead candidate AT-7687\u00a0\u00a0<\/p>\n
Weight problems-focused firm\u00a0Antag\u00a0Therapeutics is engaged on the event of peptide therapies concentrating on the GIP receptor (GIPR). GIP is an incretin hormone launched by the small gut in response to meals consumption that performs an important function within the regulation of insulin secretion, glucose metabolism, and fats storage. By concentrating on this hormone,\u00a0Antag\u00a0is aiming for higher weight reduction and metabolic advantages with out widespread unwanted side effects like these attributable to GLP-1-based therapies, similar to tolerability points and lack of muscle mass.\u00a0\u00a0\u00a0<\/p>\n
The corporate\u2019s lead candidate, AT7687, is a peptide designed as a monotherapy or to be co-administered with present or future weight problems therapies, together with GLP-1 medicines, to ship superior weight reduction and metabolic advantages. A section 1 trial for the candidate has been efficiently accomplished, by which the drug\u00a0demonstrated\u00a0a positive security and tolerability profile throughout each single ascending dose and a number of ascending dose cohorts.\u00a0Antag\u00a0mentioned it expects to start out a section 2a examine very quickly, in mid-2026.\u00a0<\/p>\n
In December 2024, the Denmark-based biotech firm\u00a0secured\u00a0\u20ac80 million ($84 million) in a collection A financing spherical, which was led by Versant Ventures and included participation from founding investor Novo Holdings, amongst others.\u00a0\u00a0\u00a0<\/p>\n
Platform know-how:\u00a0TransCon\u00a0\u00a0Illness areas: Endocrinology, uncommon ailments, and oncology\u00a0\u00a0Latest information: Acquired FDA approval for YUVIWEL for kids with achondroplasia\u00a0<\/p>\n
Ascendis Pharma is a biotech firm primarily based in Hellerup, Denmark, centered on the event of improved therapies that tackle unmet medical wants. The corporate has a platform know-how known as\u00a0TransCon, which permits it to decelerate the discharge of a drug as soon as contained in the physique, considerably decreasing the frequency of injections wanted to deal with a power situation.\u00a0\u00a0\u00a0<\/p>\n
TransCon\u00a0refers to \u201ctransient conjugation,\u201d which is the power to briefly hyperlink an inert service to a father or mother drug with identified biology. Relying on the service used,\u00a0TransCon\u00a0prodrugs might be designed to behave systemically or regionally, centered on assembly a particular therapeutic objective.\u00a0TransCon\u00a0is extensively relevant to proteins, peptides, or small molecules in a number of therapeutic areas.\u00a0\u00a0<\/p>\n
Ascendis has a pipeline centered on oncology and uncommon ailments involving endocrinology. In 2021, it had its first product\u00a0authorized\u00a0by the FDA, named SKYTROFA, which is a therapy for\u00a0pediatric\u00a0development hormone deficiency. Individuals with this uncommon illness require day by day injections, and lots of sufferers are identified to skip doses in the course of the week because of the excessive frequency\u00a0required. In distinction, Ascendis\u2019 therapy\u00a0should\u00a0solely\u00a0be taken as soon as every week, decreasing the burden for sufferers. \u00a0\u00a0<\/p>\n
Ascendis additionally\u00a0introduced\u00a0in 2023 that the European Fee had authorized one other considered one of its merchandise, known as YORVIPATH, for the therapy of adults with power hypoparathyroidism, a uncommon situation the place the parathyroid glands, that are within the neck close to the thyroid gland, produce too little parathyroid hormone. The FDA then adopted go well with in 2024 by\u00a0approving\u00a0YORVIPATH within the U.S. Most not too long ago, in February 2026, the FDA additionally\u00a0authorized\u00a0Ascendis\u2019 YUVIWEL, making it the primary once-weekly therapy indicated to extend linear development in youngsters two years of age and older with achondroplasia (a genetic skeletal dysplasia attributable to an FGFR3 mutation that inhibits bone development on the development plates) with open epiphyses, and the one therapy to offer steady systemic publicity to C-type natriuretic peptide (CNP) \u2013\u00a0 a potent signaling protein that stimulates bone development \u2013 over the weekly dosing interval.\u00a0<\/p>\n
Illness space: Infectious ailments\u00a0\u00a0Latest information: Acquired approval in Canada for chikungunya vaccine VIMKUNYA\u00a0\u00a0<\/p>\n
Bavarian Nordic is a pioneer within the vaccine area and has constructed its basis round poxviral-based vaccine platform applied sciences,\u00a0specifically,\u00a0its proprietary know-how Modified Vaccinia Ankara \u2013 Bavarian Nordic (MVA-BN). MVA-BN is an adaptable platform appropriate for addressing all kinds of infectious ailments and cancers. It’s a additional attenuated model of the Modified Vaccinia Ankara (MVA) virus, which is a extremely attenuated pressure of the poxvirus Chorioallantois Vaccinia virus Ankara (CVA).\u00a0\u00a0<\/p>\n
The corporate is a worldwide chief in smallpox vaccines and has been a long-term provider to the U.S. authorities of a non-replicating smallpox vaccine, which has been\u00a0authorized by the FDA, and can be meant to\u00a0shield in opposition to monkeypox. The vaccine can be authorized as a smallpox and monkeypox vaccine in\u00a0Canada\u00a0and as a smallpox vaccine in\u00a0Europe.\u00a0\u00a0\u00a0<\/p>\n
Extra not too long ago, Bavarian Nordic additionally\u00a0acquired\u00a0FDA approval for its virus-like particle single-dose chikungunya (a virus unfold by mosquitoes that may trigger signs like fever and joint ache) vaccine, offered below the model title VIMKUNYA. It’s the first chikungunya vaccine authorized for folks as younger as 12 years outdated, addressing an unmet want for chikungunya prevention for youthful\u00a0vacationers. The corporate\u2019s vaccine additionally\u00a0acquired approval\u00a0on the finish of final month in Canada, marking the fifth approval total for VIMKUNYA.\u00a0\u00a0<\/p>\n
Know-how: Antibody therapies\u00a0\u00a0\u00a0Illness space: Oncology\u00a0\u00a0Latest information: Acquired European Fee approval for TEPKINLY together with lenalidomide and rituximab for follicular lymphoma.\u00a0<\/p>\n
Based in 1999 in Denmark, worldwide biotech firm Genmab has invented next-generation antibody know-how platforms and\u00a0leveraged\u00a0translational, quantitative, and information sciences, leading to a pipeline together with\u00a0bispecific antibodies\u00a0and ADCs geared toward tackling most cancers. To assist develop and ship these novel antibody therapies to sufferers, Genmab has fashioned greater than 20 strategic partnerships with biotech and pharma firms, similar to AbbVie, Janssen, Amgen, and BioNTech.\u00a0\u00a0\u00a0<\/p>\n
The corporate already has eight of its merchandise available on the market. Its most up-to-date approval got here in the beginning of this month after the European Fee\u00a0granted\u00a0advertising authorization for TEPKINLY (epcoritamab) together with lenalidomide and rituximab for the therapy of grownup sufferers with relapsed or refractory follicular lymphoma.\u00a0Epcoritamab\u00a0has already acquired regulatory approval in sure lymphoma indications in additional than 65\u00a0territories, and\u00a0is being co-developed with AbbVie as a part of the businesses\u2019 oncology collaboration. The businesses share business tasks within the U.S. and Japan, with AbbVie liable for additional world commercialization.\u00a0<\/p>\n
The\u00a0firm additionally\u00a0opened\u00a0a brand new web site final yr in New Jersey to develop its U.S. presence and to turn into a totally built-in biotech firm that may additionally commercialize and ship its medication to sufferers quite than counting on exterior firms to take action. \u00a0\u00a0<\/p>\n
Know-how: Peptide therapies\u00a0\u00a0Illness areas: Metabolic and fibrotic ailments\u00a0\u00a0Latest information:\u00a0Submitted\u00a0a scientific trial utility in Germany for a section 1\/2a trial of inside lead candidate GUB-UCN2\u00a0<\/p>\n
Organized into three\u00a0most important enterprise\u00a0areas \u2013 biotech, CRO, and ventures \u2013\u00a0Gubra\u00a0is ready to\u00a0generate a gentle money circulate from its CRO enterprise whereas investing in high-impact biotech analysis and improvement (R&D) initiatives with important worth inflection potential by partnerships. The corporate has round 300 staff and had a income of DKK 2.6 billion (round $400 million) in 2025.\u00a0<\/p>\n
Gubra\u2019s lead inside program, GUB-UCN2, is predicated on a differentiated CRHR2-selective mechanism designed to ship enchancment of bodily perform and preservation or enhance of muscle mass in sufferers present process incretin-based weight reduction therapy. In February 2026, the corporate\u00a0submitted\u00a0a scientific trial utility in Germany for a section 1\/2a trial designed to judge security, tolerability,\u00a0pharmacokinetics\u00a0and preliminary efficacy of GUB-UCN2 with a selected concentrate on muscle quantity and muscle perform endpoints.\u00a0\u00a0<\/p>\n
The Danish biotech firm additionally has three important scientific partnered property in improvement. The primary candidate, now known as ABBV-295, is a long-acting amylin\u00a0analog. In March 2025, Gubra introduced\u00a0a license settlement with AbbVie to develop the candidate. In response to a\u00a0latest replace, AbbVie reported encouraging section 1 information for the asset,\u00a0demonstrating\u00a0dose-dependent and extremely aggressive weight reduction approaching 10% over 12-13 weeks in a\u00a0predominantly male, non-obese inhabitants. Gubra said that these outcomes are promising, and it seems ahead to AbbVie advancing the continuing section 1b examine in overweight sufferers, in addition to initiating section 2 of scientific improvement in Q3 2026.\u00a0<\/p>\n
The second asset is a triple agonist that’s absolutely\u00a0outlicensed\u00a0to Boehringer Ingelheim. The 2 firms\u00a0introduced\u00a0the launch of a section 1 examine for it in July 2024, with the initiation of the trial releasing a milestone cost to\u00a0Gubra. Boehringer is now progressing this system to section 2 beginning in mid 2026. In the meantime, the third asset, AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, is being developed by Gubra\u2019s accomplice\u00a0Amylyx\u00a0Pharmaceutical, which introduced its choice as a improvement candidate for post-bariatric\u00a0hypoglycemia\u00a0(PBH) and different uncommon ailments with an IND focused for 2027.\u00a0<\/p>\n
Illness space: Infectious ailments\u00a0\u00a0Latest information: Entered into settlement with Wacker Biotech to fabricate energetic protein substances for GBS vaccine\u00a0\u00a0<\/p>\n
As an\u00a0antibiotic resistance firm\u00a0primarily based in Copenhagen, Denmark, biotech\u00a0MinervaX\u00a0was\u00a0established\u00a0to create a prophylactic vaccine in opposition to group B Streptococcus (GBS) primarily based on analysis from Lund College. It’s engaged on the event of a GBS vaccine for maternal immunization since GBS could cause a probably deadly an infection in new child infants. There are presently no authorized vaccines obtainable for GBS.\u00a0<\/p>\n
MinervaX\u2019s\u00a0candidate is a protein-only vaccine primarily based on fusions of extremely immunogenic and protecting protein domains from chosen floor proteins of GBS.\u00a0\u00a0Given the broad distribution of proteins contained within the vaccine on GBS strains globally, the corporate expects that its vaccine will provide safety in opposition to\u00a0just about 100%\u00a0of all GBS isolates.\u00a0<\/p>\n
Two section 2 trials of the vaccine have been efficiently accomplished, with information exhibiting an appropriate security profile in pregnant\u00a0girls\u00a0and their infants, in addition to excessive immunogenicity, resulting in functionally energetic antibodies with the potential for broad protection and safety, in the end assuaging the necessity for extreme use of antibiotics.\u00a0\u00a0<\/p>\n
Alongside its maternal program, the Denmark-based biotech can be advancing the event of its vaccine in older adults, having not too long ago accomplished a section 1 trial.\u00a0<\/p>\n
In 2023, MinervaX\u00a0raised \u20ac54 million\u00a0($58.9 million) in upsized financing. In the meantime, in 2024, the corporate additionally\u00a0entered into\u00a0an settlement with the CDMO Wacker Biotech to fabricate its energetic protein substances for its GBS vaccine.\u00a0\u00a0\u00a0<\/p>\n
Know-how: Small molecule therapies\u00a0\u00a0Illness space: Neurodegenerative ailments\u00a0\u00a0Latest information: Was awarded a $1 million analysis grant from the Alzheimer\u2019s Affiliation to assist the continuing section 1 trial of lead candidate MNA-001\u00a0<\/p>\n
Launched\u00a0by Novo Holdings in 2021 with $73 million in collection A funding, Muna Therapeutics is targeted on the event of\u00a0small molecule therapies\u00a0for neurodegenerative ailments, together with Alzheimer\u2019s and Parkinson\u2019s illness. The corporate was fashioned\u00a0by\u00a0the mix of two European startup firms: Muna and K5 Therapeutics.\u00a0\u00a0<\/p>\n
Muna\u2019s portfolio of disease-modifying small molecule potential therapies consists of two packages that tackle the features of a key cell kind, known as microglia, which\u00a0reply to and exacerbate neurodegeneration\u00a0and compromise neuronal perform. Its lead asset, MNA-001, is a small-molecule TREM2 agonist that’s finishing section 1 of improvement and is on monitor to start section 2 testing in early Alzheimer\u2019s sufferers in early 2027.\u00a0<\/p>\n
In December 2024, Muna\u00a0entered into\u00a0a strategic alliance with GSK to\u00a0determine\u00a0and\u00a0validate\u00a0novel drug targets for the therapy of Alzheimer\u2019s. As a part of the settlement, the 2 firms mentioned they’d discover insights from Muna\u2019s\u00a0MiND-MAP platform, which applies spatial\u00a0transcriptomics\u00a0to mind samples from Alzheimer\u2019s illness sufferers, cognitively resilient people, wholesome controls, and centenarians with and with out cognitive impairment.\u00a0\u00a0<\/p>\n
The Danish biotech firm awarded\u00a0a $1 million analysis grant in January from the Alzheimer\u2019s Affiliation to assist its ongoing section 1 trial of MNA-001.\u00a0<\/p>\n
Know-how: Small molecules\u00a0Illness areas: Fertility and girls\u2019s well being\u00a0Latest information: Dosed first affected person in EU section 2 trial of RPN-002 for embryo implantation\u00a0<\/p>\n
With its major improvement workforce primarily based in Copenhagen,\u00a0ReproNovo\u00a0is aiming to deal with essential gaps in female and male fertility, in addition to girls\u2019s well being. The corporate\u2019s scientific packages prioritize mechanisms concentrating on organic drivers of infertility not adequately addressed by current interventions. In the meantime, its girls\u2019s well being analysis goals to develop therapy choices for circumstances affecting girls of reproductive age, with adenomyosis\u00a0representing\u00a0its first therapeutic focus.\u00a0<\/p>\n
The Denmark-based biotech firm has two property in scientific improvement. The primary, RPN-001 (leflutrozole), is presently being evaluated in a section 2 trial within the U.S. in males with low sperm rely and low testosterone. The candidate is an aromatase inhibitor that has the potential to induce and enhance sperm manufacturing and thereby improve the provision of sperm for fertility therapy and pure conception. By inhibiting the aromatase enzyme, it suppresses the conversion of testosterone to\u00a0estradiol, in flip rising testosterone ranges and rebalancing the testosterone to\u00a0estradiol\u00a0ratio.\u00a0<\/p>\n
ReproNovo\u2019s\u00a0second candidate, RPN-002 (nolasiban), is an oxytocin receptor antagonist being developed for embryo implantation and for the administration of adenomyosis. The corporate\u00a0introduced\u00a0on July 6 that the primary participant had been dosed in its EU section 2 scientific trial of RPN-002 for embryo implantation. The examine is evaluating two dosing regimens of the asset on uterine contractility and endocrine parameters.\u00a0\u00a0<\/p>\n
In Could 2025,\u00a0ReproNovo\u00a0raised\u00a0$65 million in collection A funding to assist it advance its pipeline.\u00a0<\/p>\n
Know-how: Small molecules\u00a0Illness space: Neurological ailments\u00a0Latest information: Secured a $2.5 million strategic funding from the Alzheimer\u2019s Drug Discovery Basis and The Affiliation for Frontotemporal Degeneration.\u00a0<\/p>\n
Vesper Bio is growing small molecule-based selective\u00a0sortilin\u00a0inhibitors as novel oral therapies for neurodegenerative and neuropsychiatric ailments. Its lead compound, VES001, is a brain-penetrant, oral therapy that targets progranulin deficiency, a serious underlying reason for a genetically pushed kind of frontotemporal degeneration.\u00a0\u00a0<\/p>\n
VES001 works by selectively stopping the degradation of progranulin whereas preserving\u00a0sortilin\u00a0ranges and features essential for neuronal well being, in distinction to antibody-mediated degradation of\u00a0sortilin. With VES001, Vesper goals to normalize ranges of progranulin and cut back neuroinflammation and illness development in each asymptomatic and symptomatic sufferers.\u00a0<\/p>\n
In October 2025, the corporate\u00a0introduced\u00a0constructive section 1b\/2a topline outcomes for VES001, which led to a greater than 95% imply enhance in progranulin ranges in comparison with baseline. It additionally had a positive security and tolerability profile in the course of the three-month day by day dosing routine, with few opposed occasions reported.\u00a0\u00a0<\/p>\n
In November 2025, the Danish biotech additionally\u00a0secured\u00a0a $2.5 million strategic funding from the Alzheimer\u2019s Drug Discovery Basis and The Affiliation for Frontotemporal Degeneration.\u00a0<\/p>\n
Know-how: Peptide therapies\u00a0\u00a0Illness space: Weight problems\u00a0\u00a0Latest information: Constructive topline section 3 outcomes have been introduced for Boehringer Ingelheim-partnered candidate\u00a0survodutide\u00a0<\/p>\n
Engaged on the event of next-generation peptide therapeutics, Zealand Pharma is targeted on therapies for varied indications, together with the extraordinarily\u00a0well-liked area of weight problems.\u00a0\u00a0<\/p>\n
The Danish biotech firm\u2019s two most superior candidates are\u00a0petrelintide\u00a0and\u00a0survodutide.\u00a0Petrelintide\u00a0is a long-acting amylin\u00a0analog\u00a0designed for weight administration. Zealand Pharma\u00a0entered into\u00a0a collaboration and license settlement with Roche by which the 2 firms are co-developing and co-commercializing\u00a0petrelintide\u00a0as each a standalone remedy and as a fixed-dose mixture with Roche\u2019s lead incretin asset CT-388. Constructive topline section 2 outcomes have been\u00a0introduced\u00a0for the candidate in March, because it achieved an as much as 10.7% imply physique weight discount at week 42 versus 1.7% with placebo.\u00a0\u00a0<\/p>\n
Survodutide, in the meantime, is a long-acting, glucagon\/GLP-1 receptor twin agonist designed to\u00a0leverage\u00a0the physique weight discount and\u00a0glycemic\u00a0management of GLP-1 receptors with some exercise on the glucagon receptors, that are current within the liver. The drug is licensed to Boehringer Ingelheim, with the large pharma solely liable for improvement and commercialization globally, whereas Zealand has co-promotion rights within the Nordic nations.\u00a0\u00a0<\/p>\n
In April, Boehringer\u00a0introduced\u00a0constructive topline outcomes from the section 3 examine of the candidate, as adults dwelling with weight problems or obese, with out kind 2 diabetes, who have been handled with\u00a0survodutide, skilled sustained weight lack of as much as a median of 16.6% after 76 weeks.\u00a0<\/p>\n
Though Denmark is considered one of Europe\u2019s smaller nations, it has a particularly well-established life sciences sector, and is residence to a number of main worldwide pharmaceutical firms, in addition to modern biotech firms like these talked about on this article \u2013 lots of that are following within the footsteps of Danish large Novo Nordisk in growing weight problems candidates.\u00a0\u00a0<\/p>\n
Denmark\u2019s authorities invests\u00a0considerably in\u00a0analysis and improvement (R&D) within the nation; it funds the educational sector, in addition to the Danish Nationwide Analysis Basis, which is an unbiased research-funding physique\u00a0established\u00a0by the Danish parliament in 1991. In 2024, the Danish authorities additionally\u00a0launched\u00a0the \u201cTechnique for Life Science In the direction of 2030\u201d imaginative and prescient, which goals to comprehend the trade\u2019s potential in direction of 2030, in flip exhibiting the federal government\u2019s dedication to the trade.\u00a0\u00a0\u00a0<\/p>\n
On high of presidency funding, there’s additionally a substantial quantity of worldwide funding within the sector.\u00a0Finally, the\u00a0mixture of private and non-private funding is a significant component within the latest success of Denmark\u2019s biotech trade.\u00a0\u00a0<\/p>\n